Pulmatrix reports Q1 loss; plans asset divestment, Cullgen merger close targeted for June

Pulmatrix, Inc.

Q1 2025 revenue $0 vs $5.9M YoY; net loss $1.8M (-$0.50 EPS) vs net income $0.825M in Q1 2024.
Cash balance $7.7M; expects to fund operations through merger close in June 2025.
Merger with Cullgen anticipated to close in June 2025; registration declared effective by SEC.
Company intends to divest assets including PUR3100 (Phase 2-ready acute migraine candidate) and iSPERSE technology.
R&D expenses decreased to less than $0.1M from $3.5M YoY due to wind-down.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.